Anabolic-androgenic steroid (AAS) use is frequently discussed in fitness communities in relation to rapid gains in muscle mass and reduced time to achieve a lean appearance. Medically, AAS are synthetic derivatives of testosterone that can increase protein synthesis, muscle fiber hypertrophy, and strength, but they also produce a characteristic risk profile affecting the endocrine system, cardiovascular health, liver, reproduction, and mental functioning. The seed concept reflected in the source text—“are you on gear”—is best understood clinically as concern for non-prescribed or non-medical AAS exposure.
Pharmacologically, AAS increase androgen receptor signaling in skeletal muscle, promoting satellite cell activation and anabolic pathways (including enhanced mTOR signaling) that support hypertrophy when paired with resistance training and adequate dietary protein and energy. However, the same hormonal manipulation can suppress the hypothalamic-pituitary-gonadal (HPG) axis. With exogenous androgens, negative feedback reduces luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased endogenous testosterone production, testicular atrophy, impaired spermatogenesis, and potential infertility. Recovery of fertility and endocrine function varies widely and may be incomplete, especially after prolonged exposure or higher doses.
AAS also have well-described adverse effects on lipids and vascular function. They can reduce high-density lipoprotein (HDL) cholesterol while increasing low-density lipoprotein (LDL) and triglycerides, thereby accelerating atherosclerotic risk. Some AAS increase blood pressure via effects on vascular tone and fluid balance, raising the likelihood of left ventricular hypertrophy and adverse cardiovascular events. Arrhythmias have been reported in vulnerable individuals due to altered myocardial electrophysiology and changes in hematocrit.
A clinically important hematologic risk is increased red blood cell mass (erythrocytosis), which elevates hematocrit and can increase blood viscosity, contributing to thrombotic phenomena. Monitoring for hypertension, hematocrit/hemoglobin, and lipid changes is therefore central to medical risk management. In liver-related toxicity, oral AAS—especially 17-alpha-alkylated compounds—carry greater hepatic risk, including cholestasis, elevated aminotransferases, and, rarely, hepatic tumors such as hepatic adenomas.
Dermatologic and metabolic effects are also common. Androgenic changes can contribute to acne, androgenic alopecia, and oily skin. Insulin sensitivity may worsen for some users, and weight gain from supraphysiologic dosing can shift body composition toward increased fat mass if caloric intake is excessive.
Mental health and behavioral correlates are more nuanced but clinically relevant. Supraphysiologic androgen exposure has been associated with mood lability, irritability, aggression, and sleep disturbance in some individuals. There is also concern for dependence and compulsive patterns driven by body-image distress, perfectionistic training behaviors, and reinforcement from visible outcomes. In the medical literature, these patterns intersect with concepts such as body dysmorphic disorder, steroid use disorder, and substance-related disorders, where continued use persists despite harm.
Regarding “aesthetics,” clinicians should frame body-image experiences through evidence-based psychological constructs rather than focusing solely on appearance. Many individuals experience pressure tied to perceived attractiveness and validation, which can reinforce maladaptive cycles of dieting, training, and hormonal manipulation. A key harm-reduction principle is recognizing that health risks accumulate over time and that “cutting” or sustained caloric restriction can compound physiological stress.
If a patient presents with suspected AAS exposure, the appropriate clinical approach includes a detailed history (dose, duration, compounds, route, stacking, cycling, concurrent substances), assessment of symptoms (chest pain, dyspnea, headaches, edema, mood changes, sexual dysfunction), and baseline laboratory evaluation. Typical investigations include a full lipid panel, liver enzymes, kidney function (creatinine), fasting glucose or HbA1c, total testosterone, LH/FSH, estradiol (when relevant), prolactin (if symptoms suggest), hematocrit/hemoglobin, and blood pressure. Electrocardiography may be warranted in those with symptoms or significant risk factors; further evaluation (e.g., echocardiography) depends on findings.
Medical management depends on goals and risks. There is no universally accepted “reversal” for all AAS effects; however, if endocrine suppression is present, clinicians may use structured follow-up and evidence-guided endocrine management strategies. For cardiovascular risk reduction, the emphasis is on addressing modifiable factors: stopping exposure, optimizing lipids, controlling blood pressure, managing sleep apnea risk, and ensuring safe training recovery. For substance-use concerns, motivational interviewing and assessment for steroid use disorder can support safer decision-making.
Harm reduction also includes discouraging unmonitored dosing and counterfeit products, minimizing polypharmacy, and ensuring clinicians coordinate care. Patients should be counseled that rapid gains do not negate long-term risk, and that persistent symptoms merit immediate medical attention.
Ultimately, “gear” conversations often center on performance and appearance, but medically, AAS exposure is best understood as deliberate endocrine manipulation with downstream effects on the HPG axis, cardiovascular system, hematology, liver, fertility, and mental health. Evidence-based screening, ongoing monitoring, and psychological support for body-image distress are key components of comprehensive care. Source: @tommyybrown_ via X (Jun 22, 2026)
Tommy Brown: They only love you when your shredded or pinning but let’s be realistic if you want to put on some size as a natural expect to stay in a surplus for a long time and say goodbye to the aesthetics. Haven’t gotten a “are you on gear” comment in so long …. #breaking
— @tommyybrown_ May 1, 2026
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
SHOP AMAZON BEST SELLERS, CLICK TO BUY FROM AMAZON.
